ScoreHaematology

NCCN-IPI in diffuse large B-cell lymphoma

Enhanced DLBCL prognostic index that grades age and LDH and counts extranodal involvement of key organs.

Updated 31 October 2026

When to use it

Patients with DLBCL at diagnosis treated with rituximab-based immunochemotherapy, to estimate overall survival.

What it needs

  • AgeOptions: ≤ 40 years · 41–60 years · 61–75 years · > 75 years
  • LDH (ratio to upper limit of normal)Options: ≤ 1 · > 1 and ≤ 3 · > 3
  • Ann Arbor stage III–IVYes or no
  • Bone marrow, CNS, liver/GI tract or lung involvementYes or no
  • ECOG ≥ 2Yes or no

The points for each answer and the automatic total are in the app.

How to interpret it

NCCN-IPI score
ResultInterpretation
≤ 1Low risk (0–1)
2–3Low-intermediate risk (2–3)
4–5High-intermediate risk (4–5)
≥ 6High risk (6–8)

Practical tip

It separates the extremes better than the IPI: 5-year OS ≈ 96% in low risk versus ≈ 33% in high risk.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top